eligibility_summary
Eligible: adults ≥18 with MDS (IPSS-R very low/low/intermediate) and symptomatic cytopenias, consent required. Contraception: WOCBP use effective method during and 3 months after, non-childbearing women must be postmenopausal/sterilized with negative pregnancy test, men sterile or use contraception. Exclude: deficiency anemias, prior SCT, HIV or active HBV/HCV, pregnancy/breastfeeding, significant comorbidities, poor compliance.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
Intervention: JSP191 (briquilimab) — a humanized IgG1 monoclonal antibody (immunotherapy, targeted biologic) given IV Day 1 of each 8-week cycle for up to 4 cycles in a 3+3 dose-escalation Phase 1 study (single arm). Mechanism of action: Binds CD117 (c-KIT) on hematopoietic stem and progenitor cells (HSPCs), blocking stem cell factor (SCF)–KIT signaling to suppress survival/maintenance and deplete CD117+ cells, aiming to reduce MDS clones and restore normal hematopoiesis. Targets: Cells — CD117+ HSPCs, including abnormal MDS stem/progenitor cells, Pathway — SCF/c-KIT (CD117) receptor tyrosine kinase signaling axis. Note: Trial was terminated for lack of improvement in clinical efficacy outcomes.